1 unchanged sentence
Rule 10 b 5 -1 Trading Arrangements
−Removed: On August 26, 2024 , Sandip Kapadia , Chief Financial Officer and Chief Administrative Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 55,000 shares of the Company’s common stock related to the exercise of options, and (ii) an indeterminable number of shares of the Company’s common stock that will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 18,812 restricted stock units previously granted, beginning on December 31, 2024 and continuing until June 30, 2025 .
−Removed: On August 27, 2024 , Jeffrey Dierks , Chief Commercial Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 28,015 shares of the Company’s common stock related to the exercise of options, and (ii) an indeterminable number of shares of the Company’s common stock that will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 2,687 restricted stock units previously granted, beginning on January 2, 2025 and continuing until June 30, 2025 .
−Removed: On September 13, 2024 , Jeffrey Dayno , President, Chief Executive Officer, and Director of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 59,293 shares of the Company’s common stock related to the exercise of options, (ii) an indeterminable number of shares of the Company’s common stock that will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 10,500 restricted stock units previously granted, beginning no earlier than December 13, 2024 and continuing until December 15, 2025 .
−Removed: During the three months ended September 30, 2024, no director or officer of the Company terminated a “ Rule 10b5-1 trading arrangement” or “ non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: On February 26, 2025 , Andrew Serafin , Chief Strategy Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 50,000 shares of the Company’s common stock related to the exercise of options, beginning on May 28, 2025 and continuing until May 31, 2026.
+Added: On February 28, 2025 , Jeffrey Dierks , the former Chief Commercial Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 48,765 shares of the Company’s common stock related to the exercise of options, and (ii) an indeterminable number of shares of the Company’s common stock that will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 45,000 restricted stock units previously granted, beginning on July 1, 2025 and continuing until December 1, 2025.
+Added: This plan was terminated on March 31, 2025 .
+Added: On March 4, 2025 , Sandip Kapadia , Chief Financial Officer and Chief Administrative Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 25,000 shares of the Company’s common stock related to the exercise of options, and (ii) up to 25,000 shares of the Company’s common stock related to the vesting of restricted stock units previously granted, beginning on July 1, 2025 and continuing until December 31, 2025.
Incorporated by Reference
14 unchanged sentences
Employment Letter between Harmony Biosciences, LLC, and Kumar Budur, as amended.
+Added: Separation Agreement by and between Jeffrey Dierks, Harmony Biosciences Holdings, Inc., Harmony Biosciences, LLC, and Harmony Biosciences Management, Inc., dated March 20, 2025.
+Added: March 24, 2025
Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024, formatted in Inline XBRL:
+Added: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025, formatted in Inline XBRL:
(i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders ’ Equity and (vi) Notes to Financial Statements, tagged as blocks of text and including detailed tags.
12 unchanged sentences
President, Chief Executive Officer and Director (principal executive officer)
−Removed: October 29, 2024
/s/ Sandip Kapadia
1 unchanged sentence
Chief Financial Officer and Chief Administrative Officer (principal financial officer)
−Removed: October 29, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.